Porcine coronavirus vaccines
The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.
1. An immunogenic composition comprising an antigen of a porcine epidemic diarrhea virus (PEDV) and an adjuvant, wherein the PEDV antigen comprises: a spike protein encoded by a nucleic acid sequence having at least 97.91% sequence identity to SEQ ID NO: 46, or having at least 98% sequence identity to SEQ ID NO: 52 or a spike protein encoded by the nucleic acid sequence of SEQ ID NO:30.
2. The immunogenic composition of claim 1 , wherein the antigen is a recombinant antigen.
3. The immunogenic composition of claim 2 , wherein the recombinant antigen comprises: (i) a PEDV spike protein having an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 47 or having at least 98% sequence identity to SEQ ID NO: 53; (ii) a PEDV spike protein having an amino acid sequence of SEQ ID NO: 31 or 35; (iii) a polynucleotide encoding the PEDV spike protein having the amino acid sequence with at least 90% sequence identity to SEQ ID NO: 47 or 53; and/or (iv) a polynucleotide encoding the PEDV spike protein having the amino acid sequence of SEQ ID NO:31 or 35.
4. The immunogenic composition of claim 2 , wherein the recombinant antigen comprises a M, E, S, or N protein of PEDV.
5. The immunogenic composition of claim 2 , wherein the recombinant antigen is a recombinant vector, a recombinant PEDV spike protein, or a combination thereof.
6. The immunogenic composition of claim 1 , wherein the adjuvant is an oil-in-water emulsion.
7. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable carrier and/or an excipient.
8. The immunogenic composition of claim 1 , further comprising an antigen of a porcine deltacoronavirus (PDCoV).
9. The immunogenic composition of claim 8 , wherein the PDCoV comprises: (i) a polynucleotide having at least 99% sequence identity to SEQ ID NO: 2, 6, or 10; (ii) a polynucleotide having at least 99% sequence identity to a RNA complement of SEQ ID NO: 1, 5, or 9; (iii) a polynucleotide having the RNA complement of SEQ ID NO: 3; (iv) a spike protein encoded by a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO: 7, 11 or 17; and/or (v) a polynucleotide encoding the PEDV spike protein having the amino acid sequence of SEQ ID NO:27.
10. The immunogenic composition of claim 9 , wherein the antigen of the PDCoV is an inactivated whole PDCoV.
11. The immunogenic composition of claim 9 , wherein the antigen of the PDCoV is a recombinant antigen comprising: (i) a PDCoV spike protein having at least 99% sequence identity to SEQ ID NO: 8, 12 or 18; (ii) a PDCoV spike protein having the amino acid sequence of SEQ ID NO: 4 or 28; (iii) a polynucleotide encoding the PDCoV spike protein having at least 99% sequence identity to SEQ ID NO: 8, 12 or 18; and/or a polynucleotide encoding the PDCoV spike protein having the amino acid sequence of SEQ ID NO: 4 or 28.